275 related articles for article (PubMed ID: 2716349)
1. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.
Tanimoto M; Scheinberg DA; Cordon-Cardo C; Huie D; Clarkson BD; Old LJ
Leukemia; 1989 May; 3(5):339-48. PubMed ID: 2716349
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia.
Scheinberg DA; Tanimoto M; McKenzie S; Strife A; Old LJ; Clarkson BD
Leukemia; 1989 Jun; 3(6):440-5. PubMed ID: 2725060
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
[TBL] [Abstract][Full Text] [Related]
4. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
[TBL] [Abstract][Full Text] [Related]
5. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
6. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity.
Caron PC; Jurcic JG; Scott AM; Finn RD; Divgi CR; Graham MC; Jureidini IM; Sgouros G; Tyson D; Old LJ
Blood; 1994 Apr; 83(7):1760-8. PubMed ID: 8142644
[TBL] [Abstract][Full Text] [Related]
7. A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody.
Ball ED; Graziano RF; Fanger MW
J Immunol; 1983 Jun; 130(6):2937-41. PubMed ID: 6574189
[TBL] [Abstract][Full Text] [Related]
8. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
Andreasen RB; Olsson L
J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
[TBL] [Abstract][Full Text] [Related]
9. Distribution of a hematopoietic-specific differentiation antigen of K562 cells in the human myeloid and lymphoid cell lineages.
Clarke BJ; Liao SK; Leeds C; Soamboonsrup P; Neame PB
Cancer Res; 1987 Aug; 47(16):4254-9. PubMed ID: 3475169
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide.
Scheinberg DA; Lovett D; Divgi CR; Graham MC; Berman E; Pentlow K; Feirt N; Finn RD; Clarkson BD; Gee TS
J Clin Oncol; 1991 Mar; 9(3):478-90. PubMed ID: 1999719
[TBL] [Abstract][Full Text] [Related]
11. Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1).
Hogg N; Ross GD; Jones DB; Slusarenko M; Walport MJ; Lachmann PJ
Eur J Immunol; 1984 Mar; 14(3):236-43. PubMed ID: 6368248
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
13. Human monoclonal antibodies reactive with human myelomonocytic leukemia cells.
Posner MR; Santos DJ; Elboim HS; Tumber MB; Frackelton AR
Cancer Res; 1989 Apr; 49(7):1665-70. PubMed ID: 2924315
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody against a differentiation antigen on human leukemia cells: cross-reactivity with rat leukemia and suppression of rat leukemia in vivo.
Johnson RJ; Shin HS
J Immunol; 1983 Jun; 130(6):2930-6. PubMed ID: 6406599
[TBL] [Abstract][Full Text] [Related]
15. Identification of a human granulocyte functional antigen (GFA-2) involved in antibody-dependent cell-mediated cytotoxicity and phagocytosis.
López AF; Begley G; Andrews P; Butterworth AE; Vadas MA
J Immunol; 1985 Jun; 134(6):3969-77. PubMed ID: 3989303
[TBL] [Abstract][Full Text] [Related]
16. Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells.
Ball ED; Kadushin JM; Schacter B; Fanger MW
J Immunol; 1982 Mar; 128(3):1476-81. PubMed ID: 6948897
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies against human myelomonocytic cells: detection of certain lineage-specific antigens on CFU-GM progenitor cells.
Takaishi M; Fu SM
J Immunol; 1985 Aug; 135(2):1523-9. PubMed ID: 2409154
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias.
Schwartz MA; Lovett DR; Redner A; Finn RD; Graham MC; Divgi CR; Dantis L; Gee TS; Andreeff M; Old LJ
J Clin Oncol; 1993 Feb; 11(2):294-303. PubMed ID: 8426207
[TBL] [Abstract][Full Text] [Related]
20. The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells.
Bühring HJ; Ullrich A; Schaudt K; Müller CA; Busch FW
Leukemia; 1991 Oct; 5(10):854-60. PubMed ID: 1720490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
